Health Canada recently published two guidance documents, effective May 23, 2018, that address the reporting of adverse reactions to marketed health products (excluding blood and blood components and cells, tissues and organs). First, Reporting Adverse Reactions to Marketed Health Products provides assistance on reporting adverse reactions to marketed health products including good case management practices. Second, Preparing and Submitting Summary Reports for Marketed Drugs and Natural Health Products addresses the format and content of annual summary reports (ASRs) and issue-related summary reports (IRSRs), as well as procedures for submission of these reports to Health Canada.
Related Publications & Articles
-
Health Canada publishes guidance on distinction between advertising and other activities for health products
Promotional messages and activities regarding a health product are subject to the advertising provisions under the Food and Drugs Act (FDA), the Controlled Drugs and Substances Act and/or their associ...Read More -
PMPRB news: New Vice Chairperson appointed, Meds Entry Watch 7th Ed. published
On August 15, 2023, the Minister of Health announced the appointment of Anie Perrault as Vice Chairperson of the Patented Medicine Prices Review Board (PMPRB) for a five-year term.Read More -
Updated and new draft Health Canada guidance documents related to medical devices
On August 30, 2023, Health Canada opened consultation on its draft pre-market guidance for machine learning-enabled medical devices (MLMD).Read More